Gilead Sciences filings document material events, operating results, governance matters and capital-structure disclosures for a Delaware biopharmaceutical company whose common stock trades as GILD on the Nasdaq Global Select Market. Form 8-K reports furnish quarterly and annual financial results, including GAAP and non-GAAP measures and reconciliations, and disclose completed acquisition activity affecting oncology pipeline assets.
Proxy and annual meeting filings record director elections, auditor ratification and shareholder voting outcomes. Other current reports cover executive and governance changes, Regulation FD disclosures, material agreements, and formal exhibits tied to Gilead’s virology and oncology business, including clinical or regulatory disclosure categories when they are part of the company’s public reporting.
Gilead Sciences Chairman & CEO Daniel O'Day disclosed open-market sales of 15,000 shares of Common Stock. On July 1, 2026, he sold 3,100 shares at an average price of $127.075 and 11,900 shares at $126.0897, according to the Form 4.
The sales were executed under a Rule 10b5-1 trading plan adopted on February 25, 2026, indicating they were pre-arranged rather than newly timed decisions. Footnotes state sale prices for the reported transactions ranged from $125.59 to $127.44, with full trade-by-trade details available on request.
Gilead Sciences executive Johanna Mercier reported open-market sales of 3,000 shares of Gilead common stock. The transactions occurred on June 15, 2026 at prices ranging from $122.79 to $125.40 per share, as described in the footnotes.
The filing states that these sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on February 20, 2025. After the transactions, Mercier directly holds 124,234 shares of Gilead common stock, according to the reported post-transaction balance.
Gilead Sciences Chief Financial Officer sells shares under trading plan
Gilead Sciences CFO Andrew D. Dickinson reported an open-market sale of 3,000 shares of common stock at $125.40 per share. After the sale, he directly holds 171,646 shares. The transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.
Gilead Sciences, Inc. officer Andrew Dickinson reported a proposed sale of 3,000 common shares, with an aggregate market value of $376,200 and an approximate sale date of June 15, 2026. The shares were acquired from the issuer as performance shares. The notice lists August 29, 2024, as the plan adoption or instruction date under Rule 10b5-1. It also reports three earlier sales of 3,000 shares each: May 15, 2026, for $396,810; April 15, 2026, for $422,880; and March 16, 2026, for $432,690 in gross proceeds.
Gilead Sciences officer Johanna Mercier reported a proposed sale of 3,000 common shares, with an aggregate market value of $371,762.10 and an approximate sale date of June 15, 2026. Morgan Stanley Smith Barney LLC is listed as broker. The shares were acquired from the issuer as performance shares on February 4, 2025, and the notice gives a Rule 10b5-1 plan adoption or instruction date of February 20, 2025.
Gilead Sciences Chief Medical Officer Dietmar Berger reported routine equity compensation activity. On June 10, 2026, he exercised 533 restricted stock units, converting them into the same number of Gilead common shares at an exercise price of $0.00 per share.
To cover associated tax obligations, 263 common shares were disposed of at $121.48 per share through a tax-withholding transaction, which is not an open-market sale. Following these transactions, he directly holds 19,252 shares of common stock and 46,928 restricted stock units, which continue to vest over a four-year schedule.
Gilead Sciences EVP and General Counsel Keeley M. Cain Wettan reported routine equity compensation activity. On June 10, 2026, 589 shares of common stock were acquired through a derivative exercise/conversion of restricted stock units at $0.00 per share.
On the same date, 283 shares of common stock were disposed of in a tax-withholding disposition at $121.48 per share to cover obligations tied to this equity event. After these transactions, the insider directly holds 5,360 shares of common stock and 19,997 restricted stock units, which vest over a four-year schedule.
Gilead Sciences Chief Financial Officer Andrew D. Dickinson reported routine equity compensation activity. On June 10, 2026, he exercised restricted stock units covering 2,796 shares of common stock at a conversion price of $0.00 per share.
To cover tax obligations, 1,341 shares of common stock were disposed of as a tax-withholding transaction at $121.48 per share, rather than through an open-market sale. Following these transactions, he holds 174,646 shares of Gilead common stock directly and 27,851 restricted stock units, which vest over a four-year schedule.
Gilead Sciences, Inc. reported that Johanna Mercier, Chief Communications & Corporate Affairs Officer, exercised restricted stock units on June 10, 2026, converting 2,796 RSUs into the same number of common shares at a stated price of 0.00 per share. Each RSU represents the right to receive one share of common stock and follows a 4-year vesting schedule.
On the same date, 1,341 common shares were disposed of in a tax-withholding transaction at 121.48 per share. Following these transactions, she directly holds 127,234 shares of Gilead common stock and has 27,851 restricted stock units outstanding.
Gilead Sciences, Inc. Chairman & CEO Daniel Patrick O'Day reported the vesting and settlement of 8,779 restricted stock units into an equal number of common shares on June 10, 2026. In connection with this vesting, 4,213 shares of common stock were withheld at $121.4800 per share to satisfy tax obligations. Following these transactions, he directly held 622,133 shares of Gilead common stock, and 92,080 restricted stock units were reported as outstanding.